Oppenheimer & CO Inc Crinetics Pharmaceuticals, Inc. Transaction History
Oppenheimer & CO Inc
- $6.42 Billion
- Q3 2024
A detailed history of Oppenheimer & CO Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 5,469 shares of CRNX stock, worth $302,818. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,469
Previous 4,699
16.39%
Holding current value
$302,818
Previous $210,000
32.86%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CRNX
# of Institutions
242Shares Held
79.6MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$348 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$345 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$326 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$274 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$247 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.98B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...